Compare · MDLN vs SINT
MDLN vs SINT
Side-by-side comparison of Medline Inc. (MDLN) and SiNtx Technologies Inc. (SINT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and SINT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.00B, about 5368.8x SINT ($8.9M).
- Over the past year, MDLN is down 10.8% and SINT is down 26.0% - MDLN leads by 15.2 points.
- MDLN has been more active in the news (21 items in the past 4 weeks vs 4 for SINT).
- MDLN has more recent analyst coverage (25 ratings vs 1 for SINT).
- Company
- Medline Inc.
- SiNtx Technologies Inc.
- Price
- $36.36-0.47%
- $2.14+2.88%
- Market cap
- $48.00B
- $8.9M
- 1M return
- -5.69%
- -10.46%
- 1Y return
- -10.77%
- -25.95%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2014
- News (4w)
- 21
- 4
- Recent ratings
- 25
- 1
SiNtx Technologies Inc.
Sintx Technologies, Inc., an advanced materials company, researches, develops, manufactures, and commercializes silicon nitride ceramics in the United States, Europe, and South America. It offers ceramic based solutions for various medical, industrial, and antipathogenic applications. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products. It has a collaboration agreement with Oxford Performance Materials, Inc. to develop a poly-ether-ketone-ketone silicon nitride composite based on OXPEKK SC solution casting technology. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies, Inc. in October 2018. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
Latest MDLN
- Principal Accounting Officer Corcoran Jessi L bought $170,750 worth of shares (5,000 units at $34.15) (SEC Form 4)
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
Latest SINT
- SEC Form SCHEDULE 13G filed by SiNtx Technologies Inc.
- SiNtx Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- SINTX Technologies Announces Raise of Approximately $5.0 Million of Capital, Including a $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
- SiNtx Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-Q filed by SiNtx Technologies Inc.
- SEC Form 4 filed by Elmore Robert Ryan
- H.C. Wainwright initiated coverage on SINTX Technologies with a new price target
- SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution
- SEC Form 10-K filed by SiNtx Technologies Inc.
- SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant